

Disproportionality analysis at the PT (Preferred Term) level of the four SOCs emerging with statistically-significant ROR in the main analysis and receiving top and high priority based on a parallel literature appraisal. In bold: statistically ROR (i.e., lower limit of the 95% confidence interval >1). Data are presented in decreasing order of frequency, when at least 5 cases were recorded (number of cases for a given PT considering ICI as a class). The sum of the number of cases for the different ICIS may be higher than the total number of cases for the drug class because a patient may have received more than one drug (anticancer combination regimen).

ENDOCRINE DISORDERS	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
Sign/symptom (Preferred Term)						
HYPOTHYROIDISM	777	6.36 (5.85-6.93)	214	5.92 (5.15-6.82)	680	6.87 (6.29-7.50)
HYPOPHYSITIS	594	20.80 (11.13-38.86)	466	56.39 (46.60-68.24)	284	12.19 (10.38-14.30)
ADRENAL INSUFFICIENCY	493	10.03 (8.88-11.33)	264	18.33 (15.92-21.10)	346	8.66 (7.61-9.86)
HYPERTHYROIDISM	422	10.09 (8.84-11.52)	159	12.89 (10.85-15.32)	370	10.91 (9.54-12.47)
HYPOPITUITARISM	197	16.60 (12.23-22.53)	128	36.67 (28.58-47.04)	110	11.40 (8.88-14.65)
THYROIDITIS	170	12.91 (10.13-16.46)	74	19.05 (14.59-24.88)	147	13.76 (10.86-17.44)
THYROID DISORDER	151	4.09 (3.42-4.88)	43	3.94 (2.89-5.36)	127	4.24 (3.50-5.12)
AUTOIMMUNE THYROIDITIS	89	9.60 (7.24-12.74)	30	10.95 (7.42-16.17)	78	10.37 (7.78-13.82)
ENDOCRINE DISORDER	65	12.59 (8.57-18.51)	47	30.87 (21.09-45.17)	29	6.92 (4.52-10.59)
HYPOTHALAMO-PITUITARY DISORDER	63	14.02 (9.12-21.56)	40	30.17 (20.04-45.42)	39	10.69 (7.09-16.12)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION	63	1.27 (0.98-1.63)	24	1.63 (1.09-2.45)	49	1.21 (0.91-1.62)
ADRENAL DISORDER	61	9.18 (6.57-12.84)	17	8.66 (5.21-14.38)	48	8.90 (6.27-12.63)
LYMPHOCYTIC HYPOPHYSITIS	59	NA	45	54.09 (29.69-98.57)	33	14.41 (8.62-24.10)
SECONDARY ADRENOCORTICAL INSUFFICIENCY	51	12.55 (8.13-19.37)	19	15.82 (9.50-26.37)	45	13.64 (8.91-20.89)
ADRENOCORTICOTROPIC HORMONE DEFICIENCY	49	19.34 (6.98-53.59)	12	16.02 (8.42-30.49)	43	20.91 (10.51-41.61)
ADRENOCORTICAL INSUFFICIENCY ACUTE	35	7.96 (5.22-12.12)	25	19.24 (12.15-30.47)	18	5.04 (3.01-8.44)
AUTOIMMUNE HYPOTHYROIDISM	27	18.82 (5.71-62.03)	5	11.79 (4.51-30.79)	25	21.47 (8.22-56.08)
PITUITARY ENLARGEMENT	26	20.13 (2.73-148.38)	25	65.58 (15.53-276.89)	8	7.63 (3.34-17.43)
BASEDOW'S DISEASE	24	5.51 (3.46-8.79)	14	10.89 (6.16-19.25)	17	4.81 (2.84-8.15)
DIABETES INSIPIDUS	22	2.55 (1.64-3.99)	12	4.72 (2.63-8.47)	12	1.72 (0.96-3.08)
GOITRE	16	1.81 (1.08-3.02)	7	2.68 (1.26-5.70)	13	1.81 (1.03-3.18)
ADDISON'S DISEASE	15	6.03 (3.31-10.99)	9	12.24 (5.97-25.12)	9	4.46 (2.17-9.14)

HYPOPARATHYROIDISM	13	10.45 (4.84-22.55)	5	13.60 (5.13-36.07)	12	11.89 (5.50-25.70)
THYROTOXIC CRISIS	12	8.65 (4.13-18.11)	12	29.28 (13.98-61.32)	8	7.10 (3.15-16.04)
SECONDARY HYPOTHYROIDISM	11	8.21 (3.85-17.53)	4	NC	8	7.36 (3.24-16.70)
SILENT THYROIDITIS	10	19.00 (2.43-148.44)	1	NC	10	23.41 (3.00-182.89)
PRIMARY HYPOTHYROIDISM	9	9.90 (4.02-24.37)	3	NC	9	12.20 (4.96-30.02)
GLUCOCORTICOID DEFICIENCY	8	18.58 (2.32-148.55)	3	NC	7	20.03 (4.16-96.41)
HYPERPROLACTINAEMIA	6	11.40 (3.48-37.36)	1	NC	5	11.70 (3.57-38.35)
THYROIDITIS ACUTE	6	9.65 (3.24-28.70)	4	NC	6	11.88 (3.99-35.36)
ADRENAL MASS	5	1.47 (0.59-3.65)	0	NC	5	1.81 (0.73-4.50)
HYPERCALCAEMIA OF MALIGNANCY	5	2.32 (0.92-5.88)	0	NC	5	2.86 (1.13-7.25)
HYPOGONADISM	5	1.97 (0.78-4.95)	5	6.67 (2.66-16.76)	3	NC
PITUITARY HAEMORRHAGE	5	7.46 (2.50-22.27)	4	NC	2	NC

HEPATOBIILIARY DISORDERS	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	Sign/symptom (Preferred Term)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases
HEPATITIS	420	3.12 (2.81-3.47)	188	4.75 (4.09-5.52)	333	3.05 (2.72-3.42)
HEPATIC FUNCTION ABNORMAL	385	1.55 (1.39-1.72)	75	1.02 (0.81-1.28)	364	1.80 (1.62-2.01)
AUTOIMMUNE HEPATITIS	373	14.23 (11.90-17.00)	161	20.85 (17.34-25.07)	303	14.24 (12.04-16.84)
LIVER DISORDER	241	1.18 (1.04-1.35)	102	1.70 (1.39-2.07)	196	1.19 (1.03-1.37)
HEPATIC FAILURE	193	0.91 (0.78-1.05)	72	1.14 (0.91-1.45)	151	0.87 (0.74-1.03)
HEPATOTOXICITY	154	1.04 (0.88-1.22)	70	1.59 (1.26-2.02)	116	0.96 (0.80-1.16)
DRUG-INDUCED LIVER INJURY	123	2.37 (1.96-2.86)	47	3.06 (2.28-4.10)	102	2.42 (1.97-2.96)
HEPATOCELLULAR INJURY	117	1.45 (1.20-1.75)	42	1.76 (1.30-2.40)	97	1.48 (1.21-1.82)
CHOLESTASIS	116	1.41 (1.17-1.70)	36	1.48 (1.06-2.06)	101	1.51 (1.24-1.85)
CHOLANGITIS	110	2.11 (1.73-2.57)	11	0.71 (0.39-1.29)	106	2.51 (2.05-3.07)
JAUNDICE	85	0.56 (0.46-0.70)	25	0.56 (0.38-0.83)	70	0.57 (0.45-0.73)
CHOLECYSTITIS	84	1.43 (1.15-1.79)	26	1.50 (1.02-2.21)	74	1.55 (1.23-1.96)
ACUTE HEPATIC FAILURE	45	1.07 (0.79-1.44)	25	2.01 (1.35-3.00)	26	0.76 (0.52-1.12)
HYPERBILIRUBINAEMIA	43	0.44 (0.33-0.60)	14	0.49 (0.29-0.83)	35	0.44 (0.32-0.62)
CHOLANGITIS SCLEROSING	37	5.06 (3.49-7.32)	1	NC	36	6.06 (4.17-8.81)
CHOLELITHIASIS	36	0.47 (0.34-0.65)	14	0.61 (0.36-1.04)	24	0.38 (0.26-0.57)
LIVER INJURY	34	0.74 (0.53-1.05)	9	0.67 (0.35-1.28)	28	0.75 (0.52-1.10)
HEPATITIS ACUTE	31	1.27 (0.88-1.82)	7	0.97 (0.46-2.04)	30	1.51 (1.04-2.18)
CHOLECYSTITIS ACUTE	28	0.98 (0.67-1.43)	6	0.71 (0.32-1.58)	24	1.03 (0.69-1.55)
JAUNDICE CHOLESTATIC	24	1.04 (0.69-1.57)	3	NC	23	1.23 (0.81-1.86)
HEPATITIS CHOLESTATIC	22	1.28 (0.83-1.97)	9	1.77 (0.91-3.44)	16	1.15 (0.70-1.89)
HEPATOMEGALY	22	0.36 (0.23-0.54)	14	0.77 (0.45-1.30)	10	0.20 (0.11-0.37)
HEPATIC PAIN	21	1.17 (0.76-1.82)	5	0.95 (0.39-2.28)	20	1.38 (0.88-2.16)
HEPATIC LESION	20	0.67 (0.43-1.05)	9	1.02 (0.53-1.97)	14	0.58 (0.34-0.98)
HEPATITIS FULMINANT	19	1.17 (0.74-1.86)	6	1.25 (0.56-2.81)	17	1.29 (0.79-2.10)
BILE DUCT OBSTRUCTION	16	0.72 (0.44-1.19)	8	1.22 (0.61-2.45)	15	0.83 (0.50-1.39)
GALLBLADDER DISORDER	16	0.56 (0.34-0.92)	6	0.71 (0.32-1.59)	11	0.47 (0.26-0.86)

HEPATIC CIRRHOSIS	16	0.29 (0.18-0.47)	2	NC	15	0.33 (0.20-0.56)
BILE DUCT STENOSIS	15	1.66 (0.98-2.81)	7	2.62 (1.23-5.57)	12	1.63 (0.91-2.93)
HEPATIC STEATOSIS	15	0.24 (0.14-0.39)	5	0.27 (0.11-0.64)	12	0.23 (0.13-0.41)
PORTAL VEIN THROMBOSIS	15	0.65 (0.39-1.08)	7	1.02 (0.48-2.16)	11	0.58 (0.32-1.06)
HYPERTRANSAMINASAEMIA	14	0.79 (0.46-1.35)	5	0.96 (0.40-2.32)	11	0.77 (0.42-1.40)
OCULAR ICTERUS	14	0.95 (0.56-1.63)	7	1.61 (0.76-3.41)	10	0.84 (0.45-1.57)
HEPATOBIILIARY DISEASE	12	2.26 (1.24-4.11)	4	NC	10	2.32 (1.21-4.44)
HEPATIC NECROSIS	10	0.47 (0.25-0.87)	5	0.79 (0.33-1.91)	7	0.40 (0.19-0.85)
HEPATITIS TOXIC	8	0.68 (0.33-1.37)	1	NC	8	0.83 (0.41-1.69)
HEPATIC CYST	7	0.74 (0.35-1.57)	1	NC	6	0.78 (0.35-1.76)
HEPATORENAL SYNDROME	7	0.58 (0.27-1.22)	3	NC	4	NC
BILE DUCT STONE	6	0.65 (0.29-1.46)	3	NC	4	NC
GALLBLADDER ENLARGEMENT	6	1.33 (0.58-3.05)	2	NC	4	NC
HEPATIC HAEMORRHAGE	6	0.95 (0.42-2.15)	2	NC	5	0.98 (0.40-2.38)
HEPATOSPLENOMEGALY	6	0.34 (0.15-0.75)	3	NC	6	0.41 (0.18-0.93)
MIXED LIVER INJURY	6	1.69 (0.74-3.90)	3	NC	4	NC
VANISHING BILE DUCT SYNDROME	6	2.85 (1.20-6.74)	0	NC	6	3.51 (1.48-8.31)
BILIARY COLIC	5	1.24 (0.50-3.07)	0	NC	5	1.53 (0.62-3.78)
BILIARY DILATATION	5	0.49 (0.20-1.20)	0	NC	5	0.61 (0.25-1.47)
BILIARY TRACT DISORDER	5	0.64 (0.26-1.55)	0	NC	5	0.78 (0.32-1.91)
CHOLANGITIS ACUTE	5	1.11 (0.45-2.74)	0	NC	5	1.37 (0.56-3.37)
HEPATIC MASS	5	0.65 (0.27-1.58)	0	NC	5	0.80 (0.33-1.95)
ISCHAEMIC HEPATITIS	5	0.92 (0.38-2.27)	0	NC	5	1.14 (0.46-2.79)

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
Sign/symptom (Preferred Term)						
DYSпноEA	1614	0.91 (0.87-0.96)	411	0.78 (0.71-0.86)	1423	0.99 (0.94-1.05)
PNEUMONITIS	1289	4.06 (3.82-4.32)	304	3.22 (2.87-3.62)	1196	4.66 (4.38-4.97)
INTERSTITIAL LUNG DISEASE	794	1.63 (1.52-1.75)	74	0.51 (0.40-0.64)	761	1.93 (1.79-2.08)
PLEURAL EFFUSION	656	0.97 (0.90-1.05)	136	0.68 (0.57-0.81)	598	1.09 (1.01-1.19)
COUGH	646	0.88 (0.82-0.96)	128	0.59 (0.49-0.70)	580	0.98 (0.90-1.06)
RESPIRATORY FAILURE	537	1.08 (0.99-1.18)	103	0.70 (0.58-0.85)	482	1.20 (1.09-1.31)
PULMONARY EMBOLISM	413	0.80 (0.72-0.88)	131	0.86 (0.72-1.02)	325	0.77 (0.69-0.87)
LUNG DISORDER	330	1.28 (1.14-1.43)	37	0.48 (0.35-0.67)	311	1.49 (1.33-1.67)
HAEMOPTYSIS	256	1.54 (1.36-1.75)	29	0.59 (0.41-0.85)	241	1.79 (1.57-2.04)
HYPOXIA	217	0.96 (0.84-1.10)	61	0.91 (0.71-1.18)	198	1.08 (0.94-1.25)
PNEUMOTHORAX	162	1.39 (1.19-1.63)	13	0.38 (0.22-0.65)	158	1.67 (1.42-1.97)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	148	1.44 (1.22-1.70)	21	0.69 (0.45-1.06)	136	1.63 (1.37-1.94)
PNEUMONIA ASPIRATION	146	1.56 (1.32-1.85)	20	0.72 (0.47-1.12)	135	1.78 (1.50-2.12)
ACUTE RESPIRATORY FAILURE	131	1.49 (1.25-1.78)	30	1.15 (0.80-1.66)	121	1.70 (1.41-2.04)
PULMONARY OEDEMA	127	0.55 (0.46-0.66)	23	0.34 (0.22-0.51)	114	0.61 (0.50-0.73)
RESPIRATORY DISTRESS	126	0.79 (0.66-0.95)	16	0.34 (0.21-0.56)	119	0.92 (0.77-1.11)
ORGANISING PNEUMONIA	125	2.81 (2.33-3.39)	14	1.06 (0.63-1.80)	117	3.24 (2.67-3.94)
DYSпноEA EXERTIONAL	87	0.66 (0.53-0.82)	14	0.36 (0.21-0.61)	78	0.73 (0.58-0.91)
PRODUCTIVE COUGH	86	0.66 (0.53-0.82)	9	0.23 (0.12-0.45)	82	0.78 (0.62-0.97)
DYSPHONIA	84	0.47 (0.38-0.58)	7	0.13 (0.06-0.28)	80	0.55 (0.44-0.69)
ATELECTASIS	64	0.73 (0.57-0.94)	19	0.73 (0.47-1.16)	58	0.82 (0.63-1.06)
EPISTAXIS	62	0.17 (0.13-0.22)	11	0.10 (0.06-0.18)	54	0.18 (0.14-0.24)
PULMONARY HAEMORRHAGE	62	0.86 (0.67-1.11)	10	0.47 (0.25-0.87)	56	0.96 (0.73-1.25)
ACUTE RESPIRATORY DISTRESS SYNDROME	60	0.41 (0.32-0.54)	15	0.35 (0.21-0.58)	52	0.44 (0.34-0.58)
OROPHARYNGEAL PAIN	60	0.32 (0.24-0.41)	20	0.36 (0.23-0.55)	44	0.29 (0.21-0.38)
WHEEZING	58	0.71 (0.55-0.93)	11	0.46 (0.25-0.83)	53	0.80 (0.61-1.06)
LUNG INFILTRATION	56	0.44 (0.33-0.57)	16	0.42 (0.26-0.69)	45	0.43 (0.32-0.58)

RESPIRATORY DISORDER	56	0.61 (0.47-0.80)	10	0.37 (0.20-0.69)	51	0.69 (0.52-0.91)
PULMONARY MASS	48	0.76 (0.57-1.02)	9	0.48 (0.25-0.93)	39	0.77 (0.56-1.05)
RHINORRHOEA	45	0.43 (0.32-0.58)	11	0.35 (0.20-0.64)	37	0.43 (0.31-0.60)
ASTHMA	42	0.62 (0.46-0.85)	8	0.40 (0.20-0.81)	37	0.68 (0.49-0.94)
PLEURISY	39	1.03 (0.74-1.41)	5	0.44 (0.18-1.07)	37	1.20 (0.86-1.67)
ASPIRATION	35	0.89 (0.64-1.25)	9	0.78 (0.40-1.50)	33	1.04 (0.73-1.47)
PULMONARY FIBROSIS	35	0.32 (0.23-0.45)	4	NC	31	0.35 (0.25-0.50)
BRONCHOSPASM	34	0.52 (0.37-0.73)	5	0.26 (0.11-0.62)	31	0.59 (0.41-0.84)
PULMONARY TOXICITY	30	0.48 (0.34-0.69)	8	0.44 (0.22-0.87)	23	0.46 (0.30-0.69)
RESPIRATORY TRACT CONGESTION	27	1.51 (1.02-2.24)	8	1.52 (0.75-3.06)	23	1.59 (1.04-2.42)
PULMONARY ALVEOLAR HAEMORRHAGE	26	0.72 (0.49-1.06)	2	NC	24	0.82 (0.54-1.23)
ACUTE PULMONARY OEDEMA	25	0.65 (0.44-0.97)	2	NC	25	0.81 (0.54-1.20)
RESPIRATORY ARREST	23	0.37 (0.24-0.55)	7	0.38 (0.18-0.79)	17	0.33 (0.21-0.54)
TACHYPNOEA	22	0.40 (0.26-0.61)	3	NC	21	0.47 (0.30-0.72)
NASAL CONGESTION	21	0.36 (0.23-0.55)	3	NC	19	0.40 (0.25-0.63)
EMPHYSEMA	20	0.67 (0.43-1.04)	2	NC	19	0.78 (0.49-1.23)
PULMONARY HYPERTENSION	20	0.27 (0.18-0.42)	6	0.28 (0.12-0.62)	15	0.25 (0.15-0.42)
PULMONARY SARCOIDOSIS	20	6.74 (3.96-11.49)	4	NC	18	7.48 (4.32-12.94)
ALVEOLITIS ALLERGIC	18	1.09 (0.68-1.75)	1	NC	17	1.27 (0.78-2.07)
OBSTRUCTIVE AIRWAYS DISORDER	17	0.92 (0.56-1.49)	5	0.91 (0.38-2.21)	15	1.00 (0.60-1.67)
BRONCHIAL OBSTRUCTION	16	1.84 (1.10-3.07)	0	NC	16	2.26 (1.36-3.78)
BRONCHIECTASIS	16	0.70 (0.42-1.15)	1	NC	16	0.86 (0.52-1.42)
PLEURITIC PAIN	16	0.62 (0.38-1.02)	3	NC	14	0.67 (0.39-1.13)
SINUS DISORDER	16	0.58 (0.35-0.96)	2	NC	15	0.67 (0.40-1.12)
HICCUPS	15	0.35 (0.21-0.59)	3	NC	13	0.38 (0.22-0.65)
PULMONARY THROMBOSIS	15	0.50 (0.30-0.83)	3	NC	15	0.61 (0.37-1.02)
ASPHYXIA	14	0.82 (0.48-1.41)	0	NC	14	1.02 (0.59-1.73)
STRIDOR	14	0.87 (0.51-1.48)	1	NC	14	1.07 (0.62-1.82)
ALVEOLITIS	13	0.59 (0.34-1.02)	4	NC	10	0.56 (0.30-1.04)
HAEMOTHORAX	13	0.72 (0.41-1.25)	3	NC	11	0.75 (0.41-1.37)
PHARYNGEAL OEDEMA	13	0.33 (0.19-0.57)	2	NC	11	0.34 (0.19-0.63)

PULMONARY ARTERIAL HYPERTENSION	13	0.83 (0.48-1.44)	0	NC	13	1.02 (0.59-1.78)
THROAT IRRITATION	13	0.21 (0.12-0.37)	3	NC	11	0.22 (0.12-0.40)
LUNG CONSOLIDATION	12	0.36 (0.20-0.64)	6	0.61 (0.27-1.36)	10	0.37 (0.20-0.69)
EOSINOPHILIC PNEUMONIA	11	2.13 (1.14-3.97)	2	NC	9	2.15 (1.08-4.25)
PULMONARY PAIN	11	2.47 (1.32-4.64)	1	NC	11	3.05 (1.62-5.72)
THROAT TIGHTNESS	11	0.19 (0.10-0.34)	4	NC	8	0.17 (0.08-0.33)
TRACHEAL STENOSIS	11	3.54 (1.85-6.76)	0	NC	11	4.36 (2.28-8.33)
BRONCHITIS CHRONIC	10	1.24 (0.66-2.36)	0	NC	10	1.53 (0.81-2.90)
CHOKING	10	0.53 (0.28-0.99)	0	NC	10	0.65 (0.35-1.21)
HYPERCAPNIA	10	1.28 (0.68-2.43)	0	NC	10	1.58 (0.83-3.00)
HYPOPNOEA	10	2.20 (1.14-4.24)	5	3.72 (1.51-9.16)	6	1.63 (0.71-3.72)
LARYNGEAL OEDEMA	10	0.44 (0.24-0.83)	1	NC	9	0.49 (0.25-0.95)
PNEUMOMEDIASTINUM	10	0.89 (0.47-1.68)	0	NC	10	1.10 (0.58-2.07)
OROPHARYNGEAL DISCOMFORT	9	1.03 (0.53-2.02)	4	NC	5	0.71 (0.29-1.72)
RALES	9	0.33 (0.17-0.63)	2	NC	7	0.31 (0.15-0.66)
RESPIRATORY TRACT INFLAMMATION	9	4.37 (2.10-9.12)	4	NC	7	4.19 (1.87-9.42)
PNEUMOTHORAX SPONTANEOUS	8	1.67 (0.81-3.44)	0	NC	8	2.06 (1.00-4.24)
PULMONARY INFARCTION	8	0.76 (0.37-1.53)	2	NC	7	0.82 (0.38-1.73)
RESPIRATION ABNORMAL	8	1.30 (0.63-2.65)	3	NC	7	1.40 (0.65-2.99)
SPUTUM DISCOLOURED	8	0.37 (0.18-0.74)	1	NC	8	0.46 (0.23-0.92)
CHYLOTHORAX	7	1.18 (0.55-2.53)	5	2.85 (1.17-6.98)	7	1.45 (0.68-3.12)
DIFFUSE ALVEOLAR DAMAGE	7	0.48 (0.23-1.01)	2	NC	7	0.59 (0.28-1.24)
DYSPNOEA AT REST	7	0.91 (0.43-1.95)	0	NC	7	1.13 (0.53-2.40)
OESOPHAGOBRONCHIAL FISTULA	7	1.68 (0.78-3.64)	0	NC	7	2.07 (0.96-4.49)
PAINFUL RESPIRATION	7	0.96 (0.45-2.04)	1	NC	7	1.18 (0.55-2.51)
PULMONARY ARTERY THROMBOSIS	7	0.86 (0.40-1.82)	2	NC	7	1.05 (0.49-2.25)
PULMONARY CONGESTION	7	0.20 (0.09-0.42)	1	NC	7	0.25 (0.12-0.52)
BRONCHIAL DISORDER	6	1.23 (0.54-2.80)	0	NC	6	1.51 (0.66-3.46)
BRONCHIAL FISTULA	6	1.48 (0.64-3.38)	0	NC	6	1.82 (0.79-4.17)
BRONCHOPLEURAL FISTULA	6	1.53 (0.67-3.51)	1	NC	5	1.57 (0.64-3.88)
OBLITERATIVE BRONCHIOLITIS	6	0.51 (0.23-1.16)	1	NC	6	0.63 (0.28-1.42)

RESPIRATORY ACIDOSIS	6	0.66 (0.29-1.48)	0	NC	6	0.81 (0.36-1.82)
ACUTE INTERSTITIAL PNEUMONITIS	5	0.97 (0.39-2.37)	2	NC	4	NC
BRONCHIAL SECRETION RETENTION	5	2.27 (0.90-5.75)	0	NC	5	2.80 (1.11-7.08)
DRY THROAT	5	0.31 (0.13-0.74)	1	NC	4	NC
LOWER RESPIRATORY TRACT CONGESTION	5	2.09 (0.83-5.27)	0	NC	5	2.57 (1.02-6.49)
NASAL DRYNESS	5	0.30 (0.13-0.74)	0	NC	5	0.38 (0.16-0.91)
PHARYNGEAL INFLAMMATION	5	0.54 (0.22-1.32)	0	NC	5	0.67 (0.27-1.62)
RESPIRATORY DEPRESSION	5	0.55 (0.23-1.34)	1	NC	5	0.68 (0.28-1.66)
RESPIRATORY SYMPTOM	5	1.54 (0.62-3.82)	1	NC	4	NC
SINUS CONGESTION	5	0.24 (0.10-0.58)	1	NC	4	NC
SNEEZING	5	0.25 (0.10-0.60)	0	NC	5	0.31 (0.13-0.74)
SPUTUM INCREASED	5	2.13 (0.85-5.38)	0	NC	5	2.63 (1.04-6.63)

INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
PRODUCT USE IN UNAPPROVED INDICATION	1734	6.29 (5.94-6.66)	312	3.77 (3.36-4.23)	1687	7.60 (7.17-8.04)
PRODUCT USE ISSUE	1365	3.99 (3.76-4.23)	69	0.67 (0.52-0.84)	1342	4.86 (4.58-5.16)
OFF LABEL USE	1183	0.88 (0.83-0.93)	266	0.67 (0.59-0.75)	1015	0.93 (0.88-0.99)
INFUSION RELATED REACTION	365	1.05 (0.94-1.16)	79	0.77 (0.61-0.96)	315	1.11 (0.99-1.25)
FALL	320	0.60 (0.54-0.67)	78	0.49 (0.39-0.62)	263	0.61 (0.54-0.69)
PRESCRIBED OVERDOSE	262	14.64 (11.75-18.24)	232	44.34 (35.99-54.63)	51	3.50 (2.60-4.70)
INCORRECT PRODUCT STORAGE	241	6.25 (5.38-7.27)	50	4.38 (3.29-5.84)	201	6.42 (5.48-7.54)
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION	180	1.67 (1.43-1.94)	17	0.53 (0.33-0.86)	177	2.02 (1.73-2.36)
TOXICITY TO VARIOUS AGENTS	174	0.41 (0.35-0.47)	79	0.63 (0.50-0.78)	114	0.33 (0.27-0.40)
DRUG DOSE OMISSION	137	0.49 (0.41-0.58)	18	0.22 (0.14-0.34)	120	0.53 (0.44-0.63)
PRESCRIBED UNDERDOSE	121	3.51 (2.89-4.27)	15	1.47 (0.88-2.45)	119	4.26 (3.50-5.19)
RADIATION PNEUMONITIS	84	3.53 (2.79-4.46)	2	NC	83	4.30 (3.39-5.44)
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR	51	2.50 (1.87-3.35)	11	1.83 (1.00-30.32)	43	2.60 (1.90-3.56)
OVERDOSE	50	0.67 (0.50-0.89)	23	1.04 (0.69-1.57)	28	0.46 (0.32-0.67)
UNDERDOSE	50	2.21 (1.65-2.96)	5	0.75 (0.31-1.80)	47	2.56 (1.89-3.46)
CONTUSION	48	0.23 (0.17-0.30)	12	0.19 (0.11-0.34)	40	0.23 (0.17-0.32)
INTERCEPTED MEDICATION ERROR	38	2.11 (1.51-2.96)	0	NC	38	2.60 (1.86-3.64)
PRODUCT PREPARATION ERROR	38	3.24 (2.29-4.58)	15	4.33 (2.57-7.31)	25	2.63 (1.74-3.98)
INTENTIONAL PRODUCT USE ISSUE	34	0.63 (0.44-0.88)	2	NC	32	0.73 (0.51-1.03)
HIP FRACTURE	32	0.64 (0.45-0.91)	6	0.41 (0.18-0.90)	30	0.74 (0.51-1.06)
SUBDURAL HAEMATOMA	31	0.58 (0.40-0.83)	8	0.50 (0.25-1.01)	27	0.62 (0.42-0.91)
MATERNAL EXPOSURE DURING PREGNANCY	30	0.50 (0.35-0.72)	9	0.51 (0.26-0.97)	25	0.51 (0.34-0.76)
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION	28	0.86 (0.59-1.25)	1	NC	27	1.02 (0.69-1.50)
EXPOSURE VIA BODY FLUID	27	3.57 (2.36-5.41)	22	9.86 (6.28-15.47)	20	3.26 (2.04-5.21)
FEMUR FRACTURE	26	0.71 (0.48-1.05)	3	NC	23	0.77 (0.51-1.17)
HEAD INJURY	26	0.57 (0.39-0.85)	4	NC	22	0.60 (0.39-0.91)

DRUG ADMINISTRATION ERROR	25	0.51 (0.35-0.77)	12	0.84 (0.47-1.48)	14	0.36 (0.21-0.60)
RIB FRACTURE	25	0.72 (0.48-1.07)	1	NC	24	0.85 (0.56-1.27)
INTERCEPTED PRODUCT STORAGE ERROR	23	5.01 (3.13-8.00)	0	NC	23	6.17 (3.86-9.86)
SPINAL COMPRESSION FRACTURE	23	0.87 (0.57-1.32)	6	0.77 (0.34-1.72)	22	1.03 (0.67-1.57)
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	23	0.36 (0.24-0.54)	2	NC	21	0.40 (0.26-0.61)
SPINAL FRACTURE	21	0.70 (0.45-1.08)	6	0.68 (0.30-1.51)	17	0.70 (0.43-1.13)
MEDICATION ERROR	20	0.25 (0.16-0.39)	6	0.25 (0.11-0.57)	15	0.23 (0.14-0.38)
INCORRECT DOSE ADMINISTERED	18	0.11 (0.07-0.17)	5	0.10 (0.04-0.25)	16	0.12 (0.07-0.20)
FEMORAL NECK FRACTURE	17	1.23 (0.76-2.01)	2	NC	15	1.34 (0.80-2.26)
RADIATION SKIN INJURY	17	0.63 (0.39-1.03)	5	0.63 (0.26-1.52)	14	0.64 (0.38-1.09)
SUBARACHNOID HAEMORRHAGE	17	0.51 (0.31-0.82)	5	0.50 (0.21-1.21)	13	0.48 (0.27-0.82)
FRACTURE	16	0.50 (0.31-0.82)	2	NC	15	0.58 (0.35-0.97)
RADIATION NECROSIS	16	3.28 (1.92-5.59)	7	4.85 (2.25-10.46)	11	2.78 (1.49-5.19)
DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	15	1.28 (0.76-2.16)	3	NC	14	1.47 (0.86-2.52)
DRUG EFFECTIVE FOR UNAPPROVED INDICATION	15	10.11 (5.00-20.46)	0	NC	15	12.46 (6.16-25.21)
LACERATION	15	0.40 (0.24-0.67)	4	NC	12	0.40 (0.23-0.71)
POST PROCEDURAL HAEMORRHAGE	15	0.52 (0.31-0.87)	4	NC	13	0.56 (0.32-0.97)
WOUND	13	0.22 (0.13-0.38)	5	0.29 (0.12-0.69)	10	0.21 (0.11-0.39)
INCORRECT DRUG ADMINISTRATION DURATION	12	0.93 (0.52-1.65)	1	NC	11	1.05 (0.57-1.91)
ROAD TRAFFIC ACCIDENT	12	0.32 (0.18-0.56)	3	NC	9	0.29 (0.15-0.56)
INCORRECT DRUG ADMINISTRATION RATE	11	1.41 (0.76-2.60)	3	NC	8	1.26 (0.62-2.57)
LUMBAR VERTEBRAL FRACTURE	11	0.95 (0.52-1.75)	2	NC	11	1.18 (0.64-2.15)
NERVE INJURY	11	0.59 (0.33-1.08)	4	NC	7	0.46 (0.22-0.98)
POST PROCEDURAL COMPLICATION	11	0.18 (0.10-0.32)	2	NC	9	0.18 (0.09-0.35)
ACCIDENTAL EXPOSURE TO PRODUCT	10	0.32 (0.17-0.60)	2	NC	8	0.31 (0.16-0.63)
INCORRECT ROUTE OF DRUG ADMINISTRATION	10	0.46 (0.24-0.86)	0	NC	10	0.56 (0.30-1.05)
SCAR	10	0.33 (0.18-0.63)	6	0.68 (0.30-1.52)	7	0.29 (0.14-0.61)
UPPER LIMB FRACTURE	10	0.35 (0.19-0.66)	5	0.60 (0.25-1.44)	6	0.26 (0.12-0.58)
BRAIN HERNIATION	9	0.64 (0.33-1.23)	1	NC	9	0.78 (0.40-1.52)
PROCEDURAL COMPLICATION	9	0.38 (0.20-0.73)	2	NC	8	0.42 (0.21-0.83)

THORACIC VERTEBRAL FRACTURE	9	1.41 (0.72-2.78)	1	NC	8	1.55 (0.76-3.17)
WOUND DEHISCENCE	9	0.36 (0.18-0.69)	3	NC	6	0.29 (0.13-0.65)
COMPRESSION FRACTURE	8	0.61 (0.30-1.24)	0	NC	8	0.76 (0.37-1.53)
DRUG PRESCRIBING ERROR	8	0.43 (0.21-0.87)	2	NC	7	0.47 (0.22-0.99)
LIMB INJURY	8	0.23 (0.12-0.47)	0	NC	8	0.29 (0.14-0.58)
LOWER LIMB FRACTURE	8	0.36 (0.18-0.72)	2	NC	6	0.33 (0.15-0.74)
RECALL PHENOMENON	8	0.39 (0.19-0.79)	1	NC	8	0.48 (0.24-0.97)
ACCIDENTAL OVERDOSE	7	0.22 (0.11-0.47)	1	NC	6	0.24 (0.11-0.53)
CLAVICLE FRACTURE	7	1.24 (0.58-2.66)	2	NC	6	1.31 (0.58-2.98)
EXPOSURE DURING PREGNANCY	7	0.07 (0.03-0.15)	3	NC	5	0.06 (0.03-0.15)
INTENTIONAL PRODUCT MISUSE	7	0.16 (0.08-0.34)	1	NC	6	0.17 (0.08-0.38)
RADIATION INJURY	7	0.54 (0.25-1.14)	1	NC	7	0.66 (0.31-1.40)
TRAUMATIC LUNG INJURY	7	0.46 (0.22-0.97)	1	NC	6	0.48 (0.22-1.08)
WOUND SECRETION	7	0.47 (0.22-1.00)	5	1.14 (0.47-2.77)	4	NC
CONTRAINDICATED PRODUCT ADMINISTERED	6	0.16 (0.07-0.37)	0	NC	6	0.20 (0.09-0.45)
EXPIRED PRODUCT ADMINISTERED	6	0.46 (0.21-1.04)	1	NC	5	0.47 (0.20-1.15)
HUMERUS FRACTURE	6	0.52 (0.23-1.17)	0	NC	6	0.64 (0.29-1.45)
JOINT INJURY	6	0.21 (0.09-0.47)	2	NC	5	0.22 (0.09-0.52)
PROCEDURAL PAIN	6	0.37 (0.16-0.83)	0	NC	6	0.46 (0.20-1.02)
SPLENIC RUPTURE	6	0.72 (0.32-1.63)	2	NC	4	NC
TOOTH FRACTURE	6	0.41 (0.18-0.92)	1	NC	6	0.51 (0.23-1.14)
TRACHEAL OBSTRUCTION	6	4.32 (1.76-10.62)	0	NC	6	5.33 (2.17-13.08)
VASCULAR ACCESS COMPLICATION	6	1.36 (0.60-3.12)	3	NC	4	NC
ANKLE FRACTURE	5	0.32 (0.13-0.78)	1	NC	4	NC
BACK INJURY	5	0.44 (0.18-1.06)	1	NC	5	0.54 (0.22-1.31)
EXPOSURE VIA FATHER	5	0.46 (0.19-1.11)	2	NC	3	NC
FACIAL BONES FRACTURE	5	0.83 (0.34-2.03)	2	NC	4	NC
JOINT DISLOCATION	5	0.36 (0.15-0.88)	0	NC	5	0.45 (0.18-1.08)
OCCUPATIONAL EXPOSURE TO PRODUCT	5	1.12 (0.46-2.77)	0	NC	5	1.38 (0.56-3.41)
PELVIC FRACTURE	5	0.47 (0.19-1.13)	0	NC	5	0.57 (0.24-1.39)
SCRATCH	5	0.55 (0.23-1.34)	2	NC	3	NC

SUNBURN	5	0.18 (0.07-0.43)	1	NC	5	0.22 (0.09-0.53)
TRACHEAL HAEMORRHAGE	5	1.58 (0.64-3.94)	0	NC	5	1.95 (0.78-4.85)
TRANSFUSION REACTION	5	0.59 (0.24-1.44)	0	NC	5	0.73 (0.30-1.77)
TRAUMATIC INTRACRANIAL HAEMORRHAGE	5	2.27 (0.90-5.75)	0	NC	5	2.80 (1.11-7.08)

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
MALIGNANT NEOPLASM PROGRESSION	6691	5.94 (5.77-6.12)	1416	4.06 (3.84-4.30)	5806	6.42 (6.23-6.63)
METASTASES TO CENTRAL NERVOUS SYSTEM	343	2.03 (1.81-2.27)	132	2.65 (2.22-3.15)	252	1.83 (1.61-2.09)
NEOPLASM MALIGNANT	280	1.11 (0.98-1.25)	229	3.10 (2.72-3.55)	53	0.26 (0.20-0.34)
NEOPLASM PROGRESSION	140	0.36 (0.31-0.43)	45	0.40 (0.30-0.53)	102	0.33 (0.27-0.40)
METASTASES TO BONE	105	0.85 (0.70-1.04)	21	0.58 (0.37-0.89)	98	0.98 (0.80-1.20)
METASTASES TO LIVER	94	0.52 (0.42-0.63)	39	0.72 (0.53-0.99)	74	0.50 (0.40-0.63)
TUMOUR PSEUDOPROGRESSION	94	17.42 (10.64-28.52)	8	5.01 (2.44-10.28)	94	21.47 (13.11-35.15)
METASTASES TO LUNG	81	0.60 (0.48-0.75)	36	0.91 (0.65-1.26)	64	0.59 (0.46-0.75)
NEOPLASM	79	0.91 (0.73-1.15)	28	1.10 (0.76-1.59)	60	0.86 (0.66-1.11)
TUMOUR HAEMORRHAGE	68	1.70 (1.33-2.18)	22	1.86 (1.22-2.85)	53	1.64 (1.24-2.16)
CANCER PAIN	64	2.81 (2.16-3.66)	9	1.34 (0.69-2.59)	60	3.25 (2.48-4.26)
TUMOUR PAIN	61	3.32 (2.53-4.37)	19	3.50 (2.21-5.56)	51	3.42 (2.55-4.60)
LYMPHANGIOSIS CARCINOMATOSA	49	2.20 (1.64-2.96)	3	NC	47	2.60 (1.92-3.51)
METASTASIS	46	0.54 (0.40-0.72)	17	0.67 (0.42-1.09)	37	0.53 (0.39-0.74)
MALIGNANT PLEURAL EFFUSION	45	1.59 (1.17-2.16)	5	0.60 (0.25-1.44)	42	1.83 (1.34-2.51)
MALIGNANT MELANOMA	39	0.87 (0.63-1.20)	14	1.06 (0.63-1.80)	30	0.83 (0.58-1.19)
METASTASES TO MENINGES	37	1.27 (0.91-1.77)	11	1.28 (0.70-2.32)	31	1.31 (0.91-1.88)
MYELOYDYSPLASTIC SYNDROME	36	0.22 (0.16-0.31)	4	NC	32	0.24 (0.17-0.35)
BRAIN NEOPLASM	35	1.06 (0.76-1.49)	9	0.92 (0.48-1.78)	30	1.12 (0.78-1.62)
METASTATIC MALIGNANT MELANOMA	35	2.51 (1.77-3.58)	17	4.13 (2.53-6.75)	24	2.12 (1.40-3.23)
NON-SMALL CELL LUNG CANCER	35	1.26 (0.90-1.78)	4	NC	31	1.38 (0.96-1.98)
LUNG NEOPLASM MALIGNANT	34	0.40 (0.28-0.56)	2	NC	33	0.48 (0.34-0.67)
SQUAMOUS CELL CARCINOMA	31	0.47 (0.33-0.68)	9	0.47 (0.24-0.90)	24	0.45 (0.30-0.68)
BREAST CANCER	23	0.25 (0.17-0.38)	3	NC	20	0.27 (0.17-0.42)
TUMOUR ASSOCIATED FEVER	23	4.91 (3.07-7.83)	2	NC	23	6.05 (3.79-9.65)
METASTATIC NEOPLASM	22	0.57 (0.37-0.87)	8	0.70 (0.35-1.41)	17	0.54 (0.34-0.88)
TUMOUR FLARE	22	3.09 (1.96-4.85)	3	NC	22	3.80 (2.42-5.98)

ACUTE MYELOID LEUKAEMIA	21	0.10 (0.07-0.16)	2	NC	19	0.12 (0.07-0.18)
METASTASES TO LYMPH NODES	21	0.42 (0.27-0.65)	8	0.54 (0.27-1.09)	20	0.50 (0.32-0.77)
BLADDER CANCER	20	0.85 (0.54-1.33)	1	NC	19	0.99 (0.63-1.57)
METASTASES TO SPINE	20	0.67 (0.43-1.05)	5	0.57 (0.24-1.37)	17	0.71 (0.44-1.14)
METASTASES TO SKIN	19	1.52 (0.95-2.43)	9	2.44 (1.25-4.74)	14	1.38 (0.81-2.37)
PARANEOPLASTIC SYNDROME	19	1.76 (1.10-2.82)	3	NC	19	2.17 (1.36-3.48)
INTRACRANIAL TUMOUR HAEMORRHAGE	18	2.65 (1.62-4.34)	9	4.48 (2.28-8.81)	10	1.81 (0.95-3.45)
SQUAMOUS CELL CARCINOMA OF SKIN	18	0.56 (0.35-0.89)	3	NC	15	0.57 (0.34-0.96)
GASTRIC CANCER	17	0.67 (0.41-1.08)	1	NC	16	0.78 (0.47-1.28)
KERATOACANTHOMA	17	1.89 (1.15-3.11)	1	NC	16	2.19 (1.31-3.66)
MELANOMA RECURRENT	17	6.97 (3.89-12.47)	7	9.71 (4.37-21.56)	10	5.05 (2.53-10.08)
NEOPLASM RECURRENCE	17	0.38 (0.24-0.61)	10	0.76 (0.41-1.41)	17	0.47 (0.29-0.76)
METASTASES TO PERITONEUM	16	0.55 (0.34-0.91)	2	NC	15	0.64 (0.38-1.07)
BASAL CELL CARCINOMA	15	0.24 (0.14-0.39)	3	NC	14	0.27 (0.16-0.46)
COLON CANCER	15	0.34 (0.21-0.57)	2	NC	13	0.37 (0.21-0.63)
LUNG NEOPLASM	15	0.40 (0.24-0.66)	5	0.45 (0.19-1.08)	11	0.36 (0.20-0.65)
MALIGNANT PERITONEAL NEOPLASM	13	2.16 (1.21-3.83)	0	NC	13	2.66 (1.50-4.72)
PERICARDITIS MALIGNANT	13	12.94 (5.36-31.22)	0	NC	13	15.94 (6.61-38.47)
LYMPHOMA	12	0.18 (0.10-0.32)	5	0.25 (0.10-0.61)	8	0.15 (0.07-0.29)
PLASMA CELL MYELOMA	11	0.15 (0.08-0.27)	0	NC	11	0.18 (0.10-0.33)
PROSTATE CANCER	11	0.28 (0.15-0.50)	1	NC	11	0.34 (0.19-0.62)
TUMOUR NECROSIS	11	0.52 (0.28-0.94)	2	NC	10	0.58 (0.31-1.09)
CHRONIC LYMPHOCYTIC LEUKAEMIA	10	0.60 (0.32-1.13)	4	NC	6	0.44 (0.20-0.99)
MELANOCYTIC NAEVUS	10	0.70 (0.37-1.31)	2	NC	9	0.77 (0.40-1.50)
METASTASES TO ADRENALS	10	0.88 (0.47-1.66)	4	NC	6	0.65 (0.29-1.47)
ADENOCARCINOMA OF COLON	9	0.94 (0.48-1.83)	1	NC	8	1.02 (0.51-2.08)
METASTASES TO KIDNEY	9	1.45 (0.74-2.85)	2	NC	7	1.39 (0.65-2.97)
RECURRENT CANCER	9	0.26 (0.13-0.49)	3	NC	9	0.32 (0.16-0.61)
SKIN CANCER	9	0.26 (0.13-0.49)	2	NC	7	0.24 (0.12-0.52)
CHRONIC MYELOID LEUKAEMIA	8	0.20 (0.10-0.39)	2	NC	7	0.21 (0.10-0.45)
INFECTED NEOPLASM	8	5.77 (2.55-13.02)	4	NC	4	NC

SECOND PRIMARY MALIGNANCY	8	0.06 (0.03-0.12)	0	NC	8	0.08 (0.04-0.15)
SKIN PAPILLOMA	8	0.36 (0.18-0.72)	3	NC	6	0.33 (0.15-0.74)
ADENOCARCINOMA	7	0.49 (0.23-1.04)	4	NC	6	0.52 (0.23-1.16)
LEUKAEMIA	7	0.18 (0.09-0.39)	3	NC	4	NC
MALIGNANT ASCITES	7	0.63 (0.30-1.34)	0	NC	7	0.78 (0.37-1.65)
METASTASES TO SPLEEN	7	1.48 (0.69-3.19)	1	NC	7	1.82 (0.84-3.93)
ONCOLOGIC COMPLICATION	7	0.69 (0.32-1.47)	1	NC	6	0.73 (0.32-1.64)
PERICARDIAL EFFUSION MALIGNANT	7	2.52 (1.14-5.56)	1	NC	7	3.11 (1.41-6.85)
RECTAL CANCER	7	0.56 (0.26-1.19)	1	NC	6	0.59 (0.26-1.33)
SMALL CELL LUNG CANCER	7	0.59 (0.28-1.26)	0	NC	7	0.73 (0.35-1.55)
BONE CANCER	6	0.66 (0.29-1.50)	1	NC	6	0.82 (0.36-1.84)
HEPATIC CANCER	6	0.13 (0.06-0.29)	1	NC	5	0.13 (0.06-0.32)
LUNG CANCER METASTATIC	6	0.31 (0.14-0.70)	0	NC	6	0.39 (0.17-0.86)
METASTASES TO PLEURA	6	0.53 (0.23-1.18)	2	NC	4	NC
NON-SMALL CELL LUNG CANCER METASTATIC	6	0.68 (0.30-1.53)	0	NC	6	0.83 (0.37-1.88)
PANCREATIC CARCINOMA	6	0.20 (0.09-0.44)	1	NC	5	0.20 (0.08-0.49)
RENAL CANCER	6	0.21 (0.09-0.47)	0	NC	6	0.26 (0.12-0.58)
B-CELL LYMPHOMA	5	0.23 (0.09-0.55)	3	NC	4	NC
BURKITT'S LYMPHOMA	5	1.74 (0.70-4.35)	1	NC	4	NC
DIFFUSE LARGE B-CELL LYMPHOMA	5	0.13 (0.05-0.31)	1	NC	5	0.16 (0.07-0.39)
LIPOMA	5	1.17 (0.48-2.89)	0	NC	5	1.45 (0.59-3.57)
LUNG ADENOCARCINOMA RECURRENT	5	6.97 (2.38-20.38)	0	NC	5	8.58 (2.93-25.11)
METASTASES TO GASTROINTESTINAL TRACT	5	1.16 (0.47-2.86)	2	NC	4	NC
OESOPHAGEAL CARCINOMA	5	0.50 (0.21-1.21)	0	NC	5	0.62 (0.25-1.50)
OVARIAN CANCER	5	0.27 (0.11-0.65)	3	NC	5	0.33 (0.14-0.81)
PITUITARY TUMOUR	5	2.01 (0.80-5.05)	3	NC	2	NC
TUMOUR COMPRESSION	5	1.43 (0.58-3.55)	0	NC	5	1.76 (0.71-4.37)
TUMOUR EMBOLISM	5	1.56 (0.63-3.88)	0	NC	5	1.92 (0.77-4.78)
TUMOUR INVASION	5	0.92 (0.38-2.27)	1	NC	5	1.14 (0.46-2.79)